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Abstract
Current tumor neoantigen calling algorithms primarily rely on epitope/MHC binding affinity 
predictions to rank and select for potential epitope targets. These algorithms do not predict for 
epitope immunogenicity using approaches modeled from tumor-specific antigen data. Here, we 
describe peptide-intrinsic biochemical features associated with neoantigen and minor 
histocompatibility mismatch antigen (mHA) immunogenicity and present a gradient–boosting 
algorithm for predicting tumor antigen immunogenicity. This algorithm was validated in two 
murine tumor models and demonstrated the capacity to select for therapeutically active antigens. 
Immune correlates of neoantigen immunogenicity were studied in apan-cancer dataset from 
TCGA and demonstrated an association between expression of immunogenic neoantigens and 
immunity in colon and lung adenocarcinoma. Lastly, we present evidence for expression of an out-
of-frame neoantigen that was capable of driving antitumor cytotoxic T-cell responses. With the 
growing clinical importance of tumor vaccine therapies, our approach may allow for better 
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selection of therapeutically relevant TSAs, including non-classical out-of-frame antigens capable 
of driving antitumor immunity.
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Introduction
T cells can affect antitumor immune responses through recognition of tumor-specific 
antigens (TSAs) presented by major histocompatibility complex (MHC) proteins. These 
peptides include tumor neoantigens, which are classically thought of as derived from 
mutation-containing proteins that generate novel immunogenic epitopes [1]. Despite the 
ability of neoantigen therapeutic vaccines to promote tumor-specific T-cell responses in a 
number of pre-clinical models [2–4], clinical efficacy has yet to be demonstrated [5,6]. A 
significant challenge for translation of TSA therapies is the ability to select the subset of 
clinically relevant epitopes from all computationally predicted neoantigens. Many 
neoantigen prediction algorithms rely heavily on peptide/MHC binding affinity predictions 
to rank epitopes [7–14]. Unlike murine pre-clinical models, where in vivo/ex vivo methods 
to further screen for immunogenicity can be applied [3,15], no such benchtop prediction 
method for immunogenicity is currently available for humans. We have previously 
demonstrated in multiple murine models that the number of predicted neoantigens is much 
higher than the number of confirmed immunogenic neoantigens [15]. Studies demonstrate 
that in some tumors, the number of predicted neoantigens is far greater than the number of 
immunogenic neoantigens which have been identified in mouse models [16,17]. As such, the 
development of an algorithm to predict the immunogenicity of neoantigen peptides (i.e. 
variant peptides predicted to bind MHC) would be valuable for screening predicted 
neoantigens for clinical application.
In addition to conventional single nucleotide variant (SNV) neoantigens, studies have 
suggested the presence of tumor-specific mRNA splice variants [18,19], expression of non-
coding regions [20], and alternative ribosomal products [21–28], allowing an out-of-frame 
translation to occur outside the setting of an insertion/deletion (INDEL) mutation. An 
increasing need exists to define frequencies of predicted TSAs existing in an out-of-frame 
context, their clinical implications, and whether frame-filtering should be applied for 
computational neoantigen prediction. In the context of SNV tumor antigen prediction, 
allowing for out-of-frame calls may identify “pseudo-SNV” antigens (i.e. out-of-frame 
antigens that contain concurrent SNV mutations) with immunogenicity responses similar to 
what is observed in frameshift neoantigens. As a preliminary approach to identify both in- 
and out-of-frame neoantigens, we performed SNV tumor-antigen computational screening 
across all open reading frames, looking for: 1) the correlates of immunogenicity for these 
predicted neoantigens, and 2) the capacity for out-of-frame epitopes to drive antitumor 
immunity.
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Features associated with neoantigen immunogenicity remain unclear. Here, we have 
elucidated peptide-intrinsic features significantly associated with vaccine/IFNγ ELISpot–
derived immunogenicity scores of MHC class I and class II TSAs. Using gradient boosting 
with cross-validation, we developed an algorithm to predict MHC I TSA peptide 
immunogenicity based on peptide-intrinsic biochemical features. We modeled the 
immunogenicity of predicted neoantigens in the BBN963 basal-like bladder cancer model 
and demonstrated the capacity of epitopes with high predicted immunogenicity to control 
tumor growth significantly better than those with low predicted immunogenicity. This 
algorithm was additionally validated using graft-versus-leukemia (GvL) minor 
histocompatibility mismatch antigens (mHA) in the P815 mastocytoma allogeneic transplant 
model. Applying this algorithm to predicted MHC I neoantigens from a TCGA pan-cancer 
dataset, we observed significant positive association between highly immunogenic 
neoantigens (HINs; in the top 95th percentile of predicted immunogenicity score) and 
microsatellite instability (MSI) high–driven immune features in colon adenocarcinoma 
(COAD) and significant negative association between signatures of anti–PD-1 therapy 
responsiveness and HIN numbers in lung adenocarcinoma (LUAD) cancer types. Lastly, we 
provide evidence in favor of antitumor cytotoxic T-cell responses generated against a 
predicted out-of-frame neoantigen, suggesting a proportion of predicted out-of-frame SNV 
tumor antigens may be presented by the tumor to generate an immune response. Prediction 
of peptide immunogenicity on a framework of peptide/MHC binding should improve 




The B16F10 cell line was purchased from ATCC (CLR-6475) and cultured according to the 
ATCC protocol. The P815 cell line was purchased from ATCC (TIB-64), transduced with 
luciferase as previously described [29], and cultured according to the ATCC protocol. The 
BBN963, UPPL1541, and MB49 cell lines were obtained and passaged as previously 
described [15]. The T11 model was obtained and passaged as previously described [30]. All 
cells used in this study were derived from viably frozen stocks of the above cell lines, with 
aliquots derived within ≤5 passages of the original stock. No mycoplasma testing was 
performed. No further authentication was performed on cell lines directly purchased from 
ATCC (B16F10, P815) or those received directly from the deriving lab (T11: Charles M. 
Perou, UNC Lineberger; BBN963, UPPL1541: William Y. Kim, UNC Lineberger). MB49 
cell line was authenticated through transcriptomic analysis, as previously described [15].
Animal studies
All experiments described in this study were approved by the UNC Institutional Animal 
Care and Use Committee (IACUC). Animals used in this study, their vendor source, and 
respective tumor cell lines included: C57BL/6J (Jackson Laboratories; B16F10), C57BL/6 
(Charles River Laboratories; BBN963, MB49, UPPL1541), DBA/2J (Jackson Laboratories; 
P815), and BALC/c (Jackson Laboratories; T11). Tumor injection routes and cell numbers 
for all models and experiments included: B16F10: Flank subcutaneous (s.c.),105 cells; 
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BBN963: Flank s.c., 107 cells; MB49: Flank s.c., 105, UPPL1541: Flank s.c., 106, T11: 
Mammary fat pad intradermal, 104, P815: Tail vein intravenous, 3×105. Tissue collection 
and DNA/RNA isolation is described in the “Neoantigen and mHA prediction” section 
below. Graft-versus-Host disease (GvHD) scoring was performed as previously described 
[31], with score defined as the sum of five components of posture, fur, activity, skin, and 
weight loss on a 0–2 scale.
Tissue Dissociation
All single-cell suspensions mentioned in the below methods sections were derived using the 
below listed protocol. Tissues were homogenized in cold PBS using the GentleMACs 
Dissociator and the samples were passed through a 70 μM cell strainer using a 5 mL syringe 
plunger. The samples were centrifuged for seven minutes at 290 RCF, 4°C, decanting the 
supernatant. The remaining pellet was resuspended into 1 mL of ACK lysis buffer (150 mM 
NH4Cl, 10 mM, KHCO3, 0.1 nM Na2EDTA in DPBS, pH 7.3) for 2 minutes at room 
temperature before quenching with 10 mL of cold media. The samples were centrifuged for 
seven minutes at 290 RCF, 4°C, resuspended in 10 mL of cold media, and passed through a 
40 μM cell strainer.
Neoantigen and mHA prediction
Neoantigen prediction was performed as previously described [15]. Briefly, mice were 
injection with tumors (Figure 1A) in the route and counts listed above, and monitored until 
tumor size reached 100mm3 by caliper measurement ( l   x   w
2
2 , where w is the smaller of two 
perpendicular tumor axes), at which point mice were humanely sacrificed with CO2 
asphyxiation followed by cervical dislocation. P815 tumor samples were collected directly 
from cell line culture (105 cells per sample). RNA was extracted from single-cell 
suspensions of tumors using Qiagen RNeasy Mini kit (cat. # 74104), and DNA was 
extracted from single-cell suspensions of tumors and matched-normal tail clippings or livers 
using Qiagen DNeasy kit (cat. # 69504), all according to manufacturer’s protocol. Whole 
exome and transcriptome library preparation was performed using Agilent SureSelect XT 
All Exon and Illumina TruSeq Stranded mRNA library preparation kits, respectively. 
Libraries were sequenced via 2×100 runs on an Illumina HiSeq 2500 at the UNC High 
Throughput Sequencing Facility (HTSF). Tumor mutations were called using UNCeqR 
(https://lbc.unc.edu/~mwilkers/unceqr_dist/) [32], filtering for SNV mutations with at least 
5x coverage by RNA-seq. Translated 8–11mer (class I) or 15mer (class II) peptides were 
derived across all open reading frames, and then predicted for MHC binding affinity using 
NetMHCPan3.0 (http://www.cbs.dtu.dk/services/NetMHCpan-3.0/) [8]. Class I minor 
mismatch antigens were predicted similarly in the P815 model against the BALB/c 
histocompatible donor. Predicted binders were filtered by binding affinity <500 nM, 
generally accepted cutoff for immunogenicity as previously noted [6,9,33], with top epitopes 
screened for immunogenicity using a vaccine/ELISpot approach, as described below.
Vaccine/ELISpot screening
Predicted neoantigen peptides (MHC I: n = 210; MHC II: n = 68) were synthesized by New 
England Peptide (Gardner, MA), using custom peptide array technology (Supplemental Data 
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File 1). Non-tumor bearing wildtype animals were vaccinated with predicted neoantigen 
peptides of their respective predicted haplotype, given as a subcutaneous injection of a pool 
of 8 equimolar peptides (5 nmol total peptide) and 50 μg poly(I:C) (Sigma, cat. # P1530) in 
PBS. A second identical injection was repeated 6 to 7 days after primary injection. Mice 
were humanely sacrificed with CO2 asphyxiation followed by cervical dislocation 5 to 6 
days after the second injection. Spleens were harvested and prepared into single cell 
suspension, as described above. Splenocytes were plated in triplicate at 5 × 105 cells per 100 
μL media (RPMI 1640 (Gibco cat. # 11875–093) with 10% FBS (Gemini cat. # 900–108) 
onto an IFNγ capture antibody-coated ELISPOT plate (BD Biosciences, cat. # 551083) 
according to manufacturer protocol for 48–72 hours, along with 1 nmol of a single peptide 
against which the respective mouse was vaccinated. Immunogenicity was defined as the 
average number of spot-forming cells (SFC) identified using an ELISpot plate reader (AID 
Classic ERL07), with no-peptide background subtracted from each epitope.
Computational analysis
Variables used in neoantigen immunogenicity regression and modelling were derived using 
the “aaComp” command of the R package “Peptides” (v2.4; https://cran.r-project.org/web/
packages/Peptides/index.html). Using features derived from this command (Tiny, Small, 
Aliphatic, Aromatic, Non-polar, Polar, Charged, Basic, Acidic), variables were derived by 
the presence (1) or absence (0) of each feature at each absolute and relative position along 
each antigen, at the site of SNV mutation along each antigen, at the first or last 3 amino acid 
residues (beginning/end) or middle residues (middle) of each antigen, or difference (loss: −1, 
gain: 1, or no change: 0) of each feature in the mutated versus reference antigen along SNV 
mutation site.
For all GLM and predictive modeling analyses, low variance variables (defined by the 
“nearZeroVar” function of the “caret” package) were removed prior to further analysis. 
Generalized linear models (GLM) using the R “glm” function were used for all non-
modeling univariable and multivariable linear regression analyses, with significance reported 
as false discovery rate (FDR)-adjusted p-values (q-value) using the R “p.adjust” command. 
Backward stepwise regression for multivariable modelling was performed using the R 
“stepAIC” command of the “MASS” package (https://cran.r-project.org/web/packages/
MASS/index.html), optimized on Akaike Information Criterion (AIC). Backward stepwise 
regression was performed by starting with all variable candidates and testing the 
deterioration of the model with removal of each variable.
For immunogenicity prediction modeling, analyses were performed using the R package 
“caret” as a wrapper for running each multivariable approach: GLM, elastic net, random 
forest, gradient boosting, and linear and radial support vector machine methods. For cross 
validation, data were split into exploration (n = 141) and validation (n = 69) sets using the 
caret “createDataPartition” function, confirming statistically non-significant differences in 
measured immunogenicity between exploration and validation sets (Mann-Whitney p > 0.2). 
Model performance was derived from Pearson correlation coefficients between ELISpot 
immunogenicity and predicted immunogenicity scores, using a 10,000-fold cross-validation 
(2/3rd random resampling) approach within the exploration set, with the input predictor 
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variables limited to those that demonstrated significant univariable correlation in >50% of 
1000-fold bootstrapping iterations (2/3rd resampling) within the exploration set. The final 
gradient boosting machine-learning algorithm immunogenicity prediction of MHC I 
epitopes can be accessed at https://github.com/vincentlaboratories/neoag.
To explore for computation evidence of out-of-frame transcripts, StringTie (https://
ccb.jhu.edu/software/stringtie/) [34] and Trinity (https://github.com/trinityrnaseq/
trinityrnaseq/wiki) [35] were used for de novo assembly of transcripts from BBN963 RNA-
seq data, according to standard workflow provided in the above links.
Peptide treatment studies
BBN963 basal-like bladder cancer model treatment began with pre-tumor vaccination with 
30 μg of a single peptide (or no-peptide control) and 50 μg poly(I:C) adjuvant injected in 
100 μL PBS intradermally in the flank of 8–10 week old female C57BL/6 mice (Charles 
River). Twelve days after vaccination, 1×107 BBN963 cells were injected in 100 μL PBS 
subcutaneously in the flank, ipsilateral to the vaccine site. On day 21 post primary 
vaccination, animals were given a vaccine booster with 30 μg of the initial respective peptide 
with no poly(I:C) adjuvant. This booster was delivered in 100 μL PBS intradermally in the 
skin directly adjacent to the tumor. Animals were monitored for tumor growth via caliper 
measurement and survival every 2–3 days for the remainder of the study, with UNC IACUC 
defined endpoints of area >200 mm2 or ulceration >5 mm in the longest diameter.
For P815 treatment studies, 8–12 week old male BALB/c donors (Jackson Laboratory) were 
vaccinated on days 0 and 7 with 100 μg total peptide (3–4 pooled equimolar peptides, or no-
peptide control) and 50 μg poly(I:C) adjuvant in 100 μL PBS intradermally in the flank. 
DBA/2 recipients were treated with 800 rad total body irradiation on day 13. On day 14, 
splenic-derived T cells and bone marrow cells were isolated from donor BALB/c animals. T 
cells were isolated from single-cell splenocyte suspensions uisng the Miltenyi Pan T Cell 
Isolation Kit II (cat. #130-095-130), according to manufacturer’s protocol. Bone marrow 
cells were isolated as previously described [36]. Recipient DBA/2 animals were given tail-
vein IV injections of 3×106 T cells, 3×106 bone marrow cells, and 3×105 P815-luciferase 
tumor cells (or bone-marrow only control). DBA/2 recipients were given a booster vaccine 
on day 21 after primary vaccine (100 μg total peptide, 50 μg poly(I:C)), with animals 
monitored every 2–3 days for survival, with UNC IACUC defined endpoints of bilateral 
hind-limb paralysis. Luciferase imaging studies were performed on days 8, 13, 22, 26, and 
35 after transplant, using an IVIS imaging system on animals given 3 mg intraperitoneal D-
luciferin (Perkin Elmer, cat. # 122799) 10 minutes prior to imaging.
Tetramer studies
Peptide/MHC tetramer and cell surface protein staining were performed as described 
previously [37]. Briefly, viable, single-cell suspensions derived from tumors (approximately 
107 total cells) were treated with 50 nM dasatinib (Sigma-Aldrich, cat. # CDS023389) for 30 
minutes at 37°C, and then stained using approximately 10 μg/mL tetramer on ice for 30 
minutes. Tetramers were generated using the MBL Quickswitch Quant H-2 Kb Tetramer 
Kit-PE (cat. # TB-7400-K1), using peptides VALLPSVMNL or SIINFEKL irrelevant 
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control, according to manufacturer protocol. Cells were then washed and incubated on ice 
with biotin-conjugated anti-PE antibody (5 μg/ml; BioLegend; PE001) for 20 minutes, 
followed by 2 washes, then further incubation with streptavidin, R-PE conjugate (SAPE, 5 
μg/mL) for 10 minutes on ice. Cells were then washed and stained for viability using BD 
fixable viability dye FVS620 according to the manufacturer’s directions. Last, cells were Fc 
blocked (anti-mouse CD16/CD32; 2.4G2, BD Biosciences) for 10 minutes on ice, followed 
by surface staining for 20 minutes on ice with the following markers: CD45 (BV510; 30-
F11), CD4 (FITC; RM4–5), CD8 (APC/Fire-750; 53–6.7) (All antibodies purchased from 
BD Biosciences). Aquisition was performed using a BD LSRFortessa flow cytometer. 
FlowJo flow cytometry software version 10 was used for analyses of all flow cytometric 
data. Cells were selected using gates defined by single color controls and FMO or irrelevant 
tetramer controls, with tetramer-positive/negative CD8+ T cells defined within live, singlet 
(by FSC-A versus FSC-H), CD45+, CD4–/CD8+ gates.
Ex vivo T-cell expansion and cytotoxicity assays
For tetramer-sorted T-cell isolation, CD8+ T cells were isolated from BBN963 tumor single-
cell suspensions (as described above) using the Miltenyi Dead Cell Removal Kit 
(130-090-101) followed by the Miltenyi CD8a+ T Cell Isolation Kit (130-104-075), both 
according to manufacturer protocol. CD8+ T cells stained with tetramer as described above 
and sorted on the BD FACSJazz. Tetramer sorted T cells or column-sorted (Miltenyi CD8a+ 
T Cell Isolation Kit) CD8+ T cells from OT1 (C57BL/6-Tg(TcraTcrb)1100Mjb/J, Jackson 
Laboratories cat. # 003831) splenocytes were cultured in complete RPMI media (RPMI 
1640 (Gibco cat. # 11875–093) with 10% FBS (Gemini cat. # 900–108), 1% sodium 
pyruvate (100nM; Gibco cat. # 11360–070), 1% non-essential amino acids (10mM; Gibco 
cat. # 11140–050), 1% l-glutamine (Gemini cat. # 400–106), 1% HEPES buffer (1Ml 
Corning cat. # 25–060-Cl), and. 1% 2-mercaptoethanol (55nM; Gibco cat. # 2198502)) in 
the presence of recombinant murine IL7 (10 ng/mL, Peprotech cat. # 217–17), IL15 (10 
ng/mL, Peprotech cat. # 210–15), and IL2 (100 IU/mL, Peprotech cat. # 212–12) for 72 
hours. Antigen-specific T-cell expansion was performed using a previously described 
protocol [38]. Briefly, all sorted T cells were recovered at 106 cells/mL for 72 hr in RPMI 
complete media in the presence of IL7 (10 ng/mL), IL15 (10 ng/mL), and IL2 (10 ng/mL) at 
37°C and 5% CO2. T cells were then cocultured in RPMI complete media and IL7, IL15, 
and IL2, alongside peptide-pulsed DCs (2.5 μg/mL peptide) which had been pulsed 
approximately 18 hr prior to coculture. Media and cytokines were changed every 2–3 days, 
letting cells expand for 7–10 days after coculture with peptide-pulsed dendritic cells before 
downstream assays.
For flow cytometric-based cytotoxicity assays, target cells (BBN963 or an irrelevant 
splenocyte control) were pre-labelled in 5 μM CFSE for 15 minutes prior to co-culture. 
Tetramer-sorted and antigen-expanded T cells (per above section) were cocultured alongside 
targets at a 1:1 ratio, with 1×105 of each target and effector population. Cells were plated on 
a v-bottom 96-well polypropylene plate, centrifuged at 300 × g for 1 minute, and incubated 
at 37°C, 5% CO2 for 4 hours. After incubation, cells were stained using FVS700 viability 
dye (BD Biosciences, cat. # 564997) according to manufacturer’s directions. Aquisition was 
performed on a BD LSRFortessa flow cytometer. FlowJo flow cytometry software version 
Smith et al. Page 7













10 was used for analyses of all flow cytometric data. Cells were identified as targets (CFSE
+) or effectors (CFSE–), looking for percent viability among targets. Percent killing was 
reported as frequency of dead targets, background subtracted from no-effector control wells.
The cytotoxic activity of T cells was evaluated using a standard 4-hour 51Cr release assay 
[39]. In brief, 5×103 51Cr-labeled (Perkin Elmer cat. # NEZ030001MC) BBN963 target cells 
per well were plated in triplicate in a 96 well v-bottom plate with different ratios (10:1 and 
5:1 effector:target) of effector cells and incubated for 4 hours at 37°C. The supernatant was 
collected and analyzed with a gamma-counter (Perkin Elmer). Before labeling, target cells 
were incubated for 2 hours at 37°C with the specific peptides (100 nM) and washed twice 
with complete medium. Target cells were incubated with medium alone or in 1% Triton 
X-100 (Sigma-Aldrich) to determine the spontaneous and maximum 51Cr release, 
respectively. The mean percentage of specific lysis of triplicate wells was calculated as 
follows: [(test counts - spontaneous counts) / (maximum counts - spontaneous counts)] × 
100%.
TCGA data analyses
MapSplice-aligned, RSEM-quantified RNA-Seq expression matrices and survival data were 
downloaded from FireBrowse (http://firebrowse.org/). Expression matrices were merged 
between all cancer types, upper quartile normalized within each sample, and log2 
transformed. Immune gene signatures (IGS) were derived from previously described 
signatures [40–44], with expression calculated as the mean expression of each gene within 
the signature. TCGA LAML samples were omitted from analysis in order to prevent 
skewing of IGS patterns. Inclusion criteria were those defined by TCGA pan-immune 
working group, according to previous studies [17]. MHC I neoantigen expression used for 
machine-learning algorithm immunogenicity prediction were obtained from publicly 
available data derived in previous studies [17]. TCGA pan-cancer dataset (n = 11,092; 
LUAD n = 515, COAD n = 283) analyses were performed according to the above 
“Computational analysis” methods section.
Differential gene expression analysis was performed using DESeq2 (https://
bioconductor.org/packages/release/bioc/html/DESeq2.html) [45]. Gene set enrichment 
analysis (http://software.broadinstitute.org/gsea/index.jsp) [46], Ingenuity pathway analysis 
(https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis/) [47], and 
DAVID gene ontology analysis (https://david.ncifcrf.gov/) [48] were performed from 
respective web portals. T-cell receptor diversity analysis was performed from previously 
published MiXCR-derived TCR reads [17] – MiXCR is an analytic tool for TCR inference 
from whole transcriptome RNA-seq data [49].
Statistical analyses
Statistical analyses for survival (displayed as Kaplan-Meier plots) were performed using log 
rank test, with no statistical correction. Differences in cytotoxicity in tetramer-sorted 
cytotoxicity assays were determined via Welch’s t-test, with no statistical correction. 
Differences in tetramer-positive T cell populations were determined via Mann-Whitney u-
test, with no statistical correction. All above analyses were performed in Graphpad Prism 8. 
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All other analyses and corresponding statistical tests are described in the above 
“Computational analysis” methods section.
Results
Correlates of immunogenicity in class I MHC epitopes
Neoantigens and mHA were predicted in six tumor models (B16F10, BBN963, MB49, 
UPPL1541, P815, and T11), allowing us to characterize neoantigens in the H2b and H2d 
haplotypes (Figure 1B). We predicted a total of 210 MHC I epitopes and 68 MHC II 
epitopes and determined their immunogenicity using a vaccine/ELISpot screening approach. 
Distribution of epitope ELISpot scores (SFC) varied by model, with MB49, B16F10, and 
P815 tumors including nine of the 10 most immunogenic epitopes, and BBN963 including 
seven of the 10 least immunogenic epitopes (Supplementary Figure S1). MHC II epitopes 
were not predicted for P815 GvL mHA. With the goal of identifying peptide-intrinsic 
features that associated with and predicted for immunogenicity, we derived a set of features 
for each peptide, including the amino acid sequence and characteristic at each I) absolute 
position, II) relative site, III) site of mutation and changes in amino acid sequence and 
characteristic at mutational site, and IV) presence of amino acid or characteristic at the 
beginning, middle, or end of each peptide (Figure 1C).
Univariable regression considering intrinsic peptide features as the predictor variable and 
immunogenicity (measured as IFNγ ELISpot values of T cells derived from vaccinated 
mice) of class I antigens demonstrated 38 significant features (q-value <0.05; Figure 2A) 
associated with ELISpot immunogenicity. Among these features, the most significant 
positive associations were changes in the mutation position to a small amino acid 
(Mutated_position_change_of_Small_feature), valine at relative site 2 
(“Relative_site_2_V”), and basic amino acids of the reference sequence at the mutated 
position (Reference_AA_at_mutated_position_Basic). In contrast, the most signficant 
negative associations were small amino acids of the reference sequence at the mutated 
position (Reference_AA_at_mutated_position_Small), changes in the mutation position to a 
basic amino acid (Mutated_position_change_of_Basic_feature), and polar amino acids at 
position 6 (Absolute_position_6_Polar). We additionally sought to determine the correlation 
among the 38 significant features, observing relatively low correlation (Figure 2B). Features 
that demonstrated significant correlation were related, such as 1) the amino acid at the 
mutated position of the reference sequence with charged or basic features, 2) valine or small 
amino acids at absolute position 11, and 3) the presence of a valine or small amino acid at 
the last position and valine at relative site 8.
Next, we evaluated the independence of the variables identified using univariable analysis 
using multivariable regression. To increase confidence of our multivariable regression, we 
performed backward stepwise regression, optimizing on Akaike Information Criterion 
(AIC), as described in the Methods. Variables whose loss resulted in an insignificant change 
to the model performance (as measured by the AIC) were removed from the set of variables 
until no further variables could be removed without a significant decrease in model fit. 
Sixteen significant features from this step were inputted into multivariable regression. The 
resulting model of 8 features indicated 33.4% variation (p<0.0001) in immunogenicity was 
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explained by the prediction (Supplementary Figure S2A). Significant features of the 
multivariable model included valine at the last position (Last_position_V (p=0.0001)), 
tyrosine at position 3 (Absolute_position_3_Y (p=0.003)), changes in the mutated position 
to a small amino acid (Mutated_position_change_of_Small_feature (p=0.007)), cysteine at 
relative site 4 (Relative_site_4_C (p=0.012)), lysine at relative site 5 (Relative_site_5_K 
(p=0.015)), tiny amino acids at relative site 6 (Relative_site_6_Tiny (p=0.016)), basic amino 
acids of the reference sequence at the mutated position 
(Reference_AA_at_mutated_position_Basic (p=0.027)), and valine at relative site 2 
(Relative_site_2_V (p=0.041))(Supplementary Figure S2B, Supplementary Table S1). To 
ensure this model was accurately representing both Hb and Hd haplotypes, we tested the 
immunogenicity for each of these five significant features, split categorically, which 
demonstrated similar trends between both haplotypes (Supplementary Figure S3). We did 
not observe significant differences in ELISpot immunogenicity among predicted in-frame 
(n=131) and out-of-frame (n=79) epitopes, emphasizing that peptide-intrinsic features were 
the primary driver for immunogenicity (p>0.05; Supplementary Figure S4).
Correlates of immunogenicity in class II MHC epitopes
Among class II epitopes, 15 peptide-intrinsic features were significantly associated with 
ELISpot immunogenicity (GLM q-value <0.05; Figure 2C). Among the most significant 
positively associated included changes in the mutation position to a non-polar amino acid 
(Mutated_position_change_of_NonPolar_feature), valine at position 1, tyrosine at position 
6, and basic amino acid at position 2. the more significant negatively correlated feature was 
a change in the mutation position into a small amino acid 
(Mutated_position_change_of_Small_feature), which was positively correlated in class I 
epitopes. Negatively correlated features also included changes in the mutation position to a 
polar amino acid (Mutated_position_change_of_Polar_feature), and small/tiny amino acids 
at the mutated site. Among the significant features (Figure 2D), we observed one cluster of 
closely inter-correlated features (Sig 1; n=7, right-hand side of dendrogram), as well as a 
second cluster of loosely inter-correlated features (Sig 2; n=8, left-hand side of 
dendrogram). With each respective tumor model defined as a binary variable (1 = true, 0 = 
false), the mean expression of cluster 1 features was significantly correlated with the 
B16F10 model and inversely correlated with MB49, whereas the mean expression of cluster 
2 was significantly correlated with MB49 tumors (Supplementary Figure S5, Spearman q-
value <0.05). This corroborated with the greater burden of immunogenic class II neoantigens 
identified in these two models, suggesting relatively greater contribution of these two 
models (particularly MB49) in the regression outcomes. Using the same backwards AIC 
stepwise regression approach described above, multivariable GLM regression was 
performed on six features. The resulting model indicated that 50.7% variation (p<0.0001) in 
immunogenicity was explained by the prediction (Supplementary Figure S6, Supplementary 
Table S2), with three significant features (tyrosine at positive 6 (Absolute_position_6_Y), 
valine at positive 1 (Absolute_position_1_V) and changes in the mutated position to a small 
amino acid (Mutated_position_change_of_Small_feature)) primarily driving the fit 
(p=0.024, 0.002, and 1.6×10−5, respectively). As with class I epitopes, we did not observe 
significant differences in immunogenicity among predicted in-frame (n=59) and out-of-
frame (n=9) epitopes (p>0.05; Supplementary Figure S3).
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Machine-learning algorithm for immunogenicity prediction in class I MHC epitopes
Our analysis of class I epitopes using multivariable GLM suggested an optimized 
multivariable model may be able to discriminate between high- and low-immunogenicity 
peptides (Figure 2E). With the goal of designing a predictive model for neoantigen and 
mHA immunogenicity, we split our class I epitope database into an exploration (2/3 of 
epitopes, n=141) and validation (1/3 of epitopes, n=69) set (Figure 3A). Class II modeling 
was not attempted due to the low number of epitopes available within our database (n=68). 
In order to reduce noise within our model, we collapsed ELISpot scores with absolute values 
less than or equal to the absolute value of the most negative count (–53 spots) to zero. This 
was performed because we were not focused on the ability of the model to characterize exact 
immunogenicity values within the low immunogenicity range. Within the exploration set, we 
used a 10,000-fold cross-validation (2/3rd random resampling) approach, which 
demonstrated that only gradient boosting consistently performed better than chance. Our 
final gradient boosting algorithm contained seven predictive features: valine at position 1 
(Absolute_position_1_V), valine at the last position (Last_position_V), small amino acids at 
the last position (Last_position_Small), basic amino acids of the reference sequence at the 
mutated position (Reference_AA_at_mutated_position_Basic), changes in the mutated 
position to a small amino acid (Mutated_position_change_of_Small_feature), lysine at 
relative site 1 (“Relative_site_1_K”), and presence of valine within the first 3 positions 
(First_three_AA_V). The class I validation set was run through this final gradient boosting 
algorithm, demonstrating significantly accurate performance when comparing the linear fit 
between the actual immunogenicity by ELISpot and the predicted immunogenicity by 
modeling (p=0.01893, coefficient=0.30, Figure 3B). This model provided a high negative 
predictive value (83.6% predicted values <53), ideal in the setting for filtering out a large 
pool of predicted tumor antigens in order to select epitopes for therapeutic targeting.
In vivo validation of the class I immunogenicity prediction model
To test whether our final algorithm increased the likelihood of identifying clinically relevant, 
immunogenic epitopes for antitumor vaccine responses, we used two tumor models within 
our validation set: BBN963 basal-like bladder cancer neoantigens (epithelial tumor) and 
P815 mastocytoma GvL mHA (hematopietic tumor). Epitopes were binned into predicted 
high immunogenicity (top quartile) and predicted low immunogenicity (bottom quartile) 
groups for comparison of relative efficacy (Supplementary Table S3). In BBN963 tumors, 
three predicted high (B2: VALLPSVML; C2: VSLTLFSSWL; A5: SNVMQLLL) and two 
predicted low (B5: ETLLNSATI; B12: MISRNRHTL) immunogenicity neoantigens were 
identified. Animals were vaccinated with 30 μg of one peptide (or no-peptide control) 
alongside 50 μg poly(I:C) as adjuvant, challenged with tumor 12 days after vaccination, then 
given a 30 μg peptide boost on day 21 after the initial vaccination (Figure 3C). Animals 
vaccinated with predicted a high immunogenicity peptide survived longer than those 
vaccinated with either predicted low immunogenicity peptide (p=0.0006) or no-peptide 
control (p=0.0031; Figure 3D, Supplementary Figure S7A). In contrast, no significant 
difference in survival was observed between predicted low immunogenicity peptide and no-
peptide control groups (p=0.9674). We additionally observed better control of tumor size in 
animals vaccinated with predicted high immunogenicity peptide (Supplementary Figure 
S7B–D).
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In P815 tumors, two predicted high (AFQRVTCTTL and QYSSANDWTV) and three 
predicted low (HYAANEWI, KFFPNCIFL, and LYISPNPEVL) immunogenicity GvL 
mHAs were identified. BALB/c donor animals were vaccinated with a pool of predicted high 
or low immunogenicity peptides (100 μg each peptide) or no-peptide control, with 50 μg 
poly(I:C) as adjuvant on days 0 and 7. DBA/2 recipient animals were lethally irradiated on 
day 13; transplanted with 3×106 BALB/c T cells, 3×106 BALC/c bone marrow cells, and 
3×105 P815 tumor cells on day 14; and finally given a 3rd booster vaccine on day 21 (Figure 
3E). Animals given predicted high immunogenicity T cells survived longer than those given 
predicted low immunogenicity T cells (median survival 44.5 and 28 days, respectively), both 
of which survived longer than no-peptide control T cells (median survival 19 days, Figure 
3F). Additionally, we observed significantly lower tumor burden in high immunogenicity 
versus low immunogenicity peptide vaccinated animals by luciferase imaging on day 26 (p < 
0.05, Mann-Whitney u-test; Supplementary Figure S8-S9). All groups receiving donor T 
cells demonstrated measurable graft-versus-host disease (GvHD) clinically after transplant, 
without significant differences in weight loss or GvHD clinical scores between groups up to 
day 30 (Supplementary Figure S10). In summary, these experiments demonstrated the in 
vivo biological relevance of our immunogenicity prediction model, with significant 
differences observed between predicted high and low immunogenicity epitopes.
Correlates of predicted immunogenicity in human class I epitopes
Although the immunogenicity prediction algorithm was designed and validated in mice, we 
hypothesized that similar rules of immunogenicity may exist among human neoantigens. To 
study this, we ran previously predicted MHC I neoantigens from TCGA through our 
machine-learning algorithm, generating immunogenicity scores for each epitope [17]. As 
expected, we observed a correlation between the number of HINs identified by our model 
(>95th percentile) with number of total neoantigens (Pearson correlation p<0.0001; 
Supplementary Figure S11). Therefore, we performed regression studies between HIN count 
and immune features without controlling for total neoantigen burden. We observed 
significant association between HIN count and IFNγ, cytotoxicity, CD8+ T-cell and total T 
cell, and B-cell immune gene signatures (IGS) among the dataset (not controlling for cancer 
type; Figure 4A). Assessing these associations individually by tumor type, we observed that 
the most significant associations were encompassed by the colon (COAD) and lung (LUAD) 
adenocarcinoma cancer types (Figure 4B). Within COAD, ta positive association between 
HIN count and many T-cell and cytotoxicity signatures. To identify potential drivers of this 
pattern, we looked for the association between HIN count and MSI status, observing that 
MSI-high COAD tumors had significantly higher HIN counts (Figure 4C, Supplementary 
Figure S12).
In contrast, LUAD demonstrated a negative association with signatures of anti–PD-1 
responsiveness and several immune cell signatures. Regression analysis between these 
negative IGS features and LUAD oncogene/tumor suppressor copy numbers demonstrated 
preferential association with MYC copy number (q-value <0.05; Figure 4D, Supplementary 
Figure S13). To demonstrate that MYC amplification provided a pro-tumorigenic signal in 
LUAD, we observed significantly greater expression of genes corresponding with cell cycle 
gene patterns (Supplementary Figure S14A,C,D), as well as enrichment of downstream 
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genes involved in the MYC pathway (Supplementary Figure S14B) among MYC-amplified 
tumors. This increased proliferation pattern was additionally associated with decreased 
sharing of T-cell receptor sequences from tumor-infiltrating T cells in MYC-amplified 
tumors, suggesting a potentially altered antitumor immune response (Supplementary Figure 
S14E). We did not find HIN count to correlate with MYC copy number (Pearson p>0.5), 
suggesting tumor immunogenicity burden and MYC target expression may be independent 
predictors for immune exclusion and checkpoint inhibition resistance.
Out-of-frame neoantigen epitopes promote anti-tumor immunity
Through the design of our neoantigen prediction algorithm, we considered predicted tumor 
epitopes across all open reading frames. As such, subsets of our predicted neoantigens were 
frameshifted epitopes that contained a mutation. We hypothesized that through mechanisms, 
such as novel splice variants and ribosomal dysfunction, a subset of these out-of-frame 
predicted antigens could arise in the tumor, allowing for a viable target with greater 
heterogeneity from self-antigen. Indeed, two of the predicted high immunogenicity 
neoantigens used in our BBN963 vaccine studies were predicted to be out-of-frame (B2, 
C2), although still providing therapeutic efficacy over predicted low immunogenicity and 
no-peptide controls. One of these antigens (B2) demonstrated computational evidence of 
translation in the out-of-frame context using two de novo transcriptome assemblers Trinity 
[35] and StringTie [34], whereby the presence of a 5’ start codon was identified with no 
intervening stop codon up to the B2 antigen site.
With therapeutic and computational evidence in favor of B2 antigen-mediated antitumor 
immune responses against BBN963 tumors, we next confirmed the presence of B2/MHC 
tetramer–specific CD8+ T cells infiltrating within the tumor of BBN963-bearing animals, 
suggesting an antigen-driven T-cell response (Figure 5A, Supplementary Figure S15). 
Tetramer sorting and peptide-pulsed dendritic cell cocultures of B2-specific T cells 
demonstrated approximately 40-fold expansion of T cells within 10 days (<5×105 to 
>2×106), with maintenance of a B2-enriched population (Supplementary Figure S16). Using 
a flow cytometric cytotoxicity assay, coculture of B2-specific T cells with the BBN963 cell 
line demonstrated >1.7x increase in killing of target cells (15.25%) compared to the OTI T-
cell irrelevant control (8.85%). Neither B2-specific nor OTI T cells demonstrated killing of 
irrelevant splenocytes control cells (1.1% and 0.85%, respectively; Figure 5B, 
Supplementary Figure S17). B2-specific T-cell killing of BBN963 over that of OTI T-cell 
controls was additionally confirmed using a 51Cr-release cytotoxicity assay (Figure 5C). 
Altogether, these results suggested the presence of a cytotoxic CD8+ T-cell response against 
the out-of-frame B2 neoantigen in BBN963.
Discussion
The study presented here addressed two unanswered questions regarding tumor antigens: 1) 
what features of a tumor antigen sequence are associated with immunogenicity, and 2) can 
inclusion of non-canonical, out-of-frame epitopes provide viable targets for anti-tumor 
therapeutic vaccination? We demonstrated that peptide-intrinsic features of predicted tumor 
antigens could discriminate epitopes with therapeutic efficacy, and that inclusion of out-of-
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frame epitopes among this pool could provide antitumor immunity against these alternative 
antigens. We showed that reading frame was not a significant determinant for 
immunogenicity (at least among peptides with predicted binding affinity <500 nM), and that 
exclusion of frame-filtering could identify out-of-frame epitopes with therapeutic antitumor, 
cytotoxic activity. Although the optimal rules for immunogenicity may differ between in-
frame and out-of-frame tumor antigens, our relatively limited training set was underpowered 
to discriminate between these two classes. As such, future studies should be performed to 
address the biological differences between in- and out-of-frame tumor antigens, and what 
methods can most optimally identify clinically relevant epitopes in each class.
Our analysis of class I epitopes demonstrated similar trends in expression of features 
significantly associated with immunogenicity, as well as potential generalizability of our 
final gradient boosting algorithm for human MHC. We were unable to demonstrate here 
whether MHC haplotype may influence immunogenicity prediction, given our murine 
models were limited to two haplotypes. That said, it may be the case that certain features 
may significantly impact immunogenicity in a way that is conserved across haplotypes. A 
potential bias in our analysis is the variation in distribution of ELISpot scores among various 
models. This variation is likely a product of both our selection process (i.e. peptide selection 
based on a threshold predicted MHC binding affinity) as well as the number of predicted 
epitopes available for screening in each model. As methodology for antigen prediction and 
validation was conserved across all models, as well as biological validation performed 
across two independent tumor models, we do not believe there to be significant underlying 
biological differences among epitopes identified between different tumor models.
Despite the increased interest in neoantigen-based therapeutic tumor vaccine therapy, 
prediction algorithms capable of directly predicting for neoantigen immunogenicity are 
lacking [50], and no neoantigen immunogenicity predictor trained specifically on tumor 
antigen data exists. Current neoantigen immunogenicity predictors are instead trained on 
databases containing immunogenicity scores from all potential MHC-binding epitopes, of 
which the biology may not closely match that of mutation-derived tumor antigens. An 
example of this biological disparity is observed in the vastly different immune response rates 
between neoantigens and tumor-specific endogenous retroviral epitopes [51], whereby the 
concept of a “self” and “non-self” antigen is not considered as a feature for immunogenicity 
prediction among current algorithms. Training our model specifically on “self” tumor 
antigenic sources instead allows for greater specificity of selection for peptide-intrinsic 
features which correlated with ex vivo validated IFNγ release scores. Our final predictive 
algorithm demonstrated capacity to select for therapeutically relevant epitopes, as observed 
in our treatment studies where predicted high immunogenicity peptides controlled tumor 
burden significantly better than predicted low immunogenicity peptides and no-peptide 
control groups. This model demonstrated a high true-negative rate, which is ideal in the 
setting of filtering out many weakly immunogenic epitopes to select for a small pool of 
targets for therapy.
Validation experiments in BBN963 and P815 models were performed as a combination of 
prophylactic and therapeutic vaccines, rather than strictly treating animals after tumor 
injection. This method was selected due to the intrinsically low efficacy of free-peptide 
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vaccines, whereby differences in therapeutic efficacy may not be observed between 
predicted high and low immunogenicity antigens [52]. As such, although these experiments 
provided evidence for the biological relevance of our computational model, development of 
more robust therapeutic vaccine platforms are still necessary for improving response rates to 
peptide-based, tumor-specific antigen vaccines. From these studies, we observed that 
predicted high immunogenicity peptides had greater benefit in the therapeutic vaccine 
setting than predicted low immunogenicity peptides. As such, we reasoned that although 
HIN count and total neoantigen burden were correlated, the most HINs were the key drivers 
of immunity. Thus, we performed regression studies between HIN count and immune 
features without controlling for total neoantigen burden. Analysis of human neoantigen data 
from TCGA demonstrated association between presence of HINs with features of immune 
response in colon and lung adenocarcinoma. Athough the association between HIN count 
and immune gene signature expression, as well as MSI-status, in COAD agreed with the 
classical view of a tumor-antigen driven immune response, the negative association with 
immune features (including signatures of anti–PD-1 responsiveness) in LUAD is less clear. 
A report from Jerby-Arnon and colleagues demonstrates an association between resistance 
to immune checkpoint inhibition and MYC target expression [53]. As such, we initially 
hypothesized that MYC target expression may be the common driver for immune exclusion, 
anti–PD-1 non-responsiveness, as well as high HIN burden. However, MYC copy number 
did not correlate with HIN count, suggesting MYC expression and HIN burden are 
independent pathways of immune exclusion and checkpoint inhibitor resistance in LUAD. 
Further studies are necessary to more closely examine the relationship between tumor 
immunogenic neoantigen burden and immune features, elucidating why higher 
immunogenicity burden is unexpectedly negatively associated with IGS patterns.
Currently, it is not well understood what frequency of tumor antigens arise from 
conventional in-frame antigens versus non-conventional antigenic sources, such as retroviral/
retrotransponson expression, intron expression, and out-of-frame translation. A study from 
Laumont et al. suggests that non-coding regions are the main source of tumor-specific 
antigens in acute lymphoblastic leukemia patient samples [20], providing evidence that 
current methods for neoantigen prediction may be limited by filtering for in-frame exon 
regions. Laumont and colleagues used a RNA-based screening approach whereby k-mers 
derived from tumor RNA-seq reads were directly screened against matched-normal RNA k-
mers, keeping only tumor specific regions. Compared to conventional exome-based TSA 
calling, this RNA-based screening approach allowed for identification of a broader repertoire 
of epitopes, consistent with the increased frequency of non-canonical TSAs identified by 
Laumont et al. compared to this current study. Although Laumont and colleagues used a 
mass spectrometry approach to confirm expression of out-of-frame epitopes, no 
computational methods have been used to identify such non-canonical epitopes. As such, our 
study relies upon a naïve, non-biased approach for screening out-of-frame antigens, whereby 
we combined conventional exome-based SNP antigen calling with identification of potential 
epitopes across all open reading frames. We demonstrated that the frame of an epitope did 
not associate with immunogenicity, but inclusion of out-of-frame epitopes could provide 
therapeutic benefit. This analysis highlighted how some proportion of SNV neoantigens 
predicted to be out-of-frame may still maintain expression and capacity to trigger a cytotoxic 
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T-cell response against the tumor. If such antigens are further confirmed in human cancers, 
there are important implications that will need to be addressed: 1) whether the biology and 
immunogenicity of these out-of-frame “SNV” antigens more closely mirrors that of classical 
SNV-neoantigens or whether they are instead more similar to INDEL-derived neoantigens or 
alternative neoantigens, such as tumor-specific endogenous retroviral antigens; and 2) if 
reading frame filters should be applied to current neoantigen calling algorithms in order to 
most effectively capture the targetable antigen landscape of a tumor.
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Figure 1: Summary of tumor antigen prediction and identification of peptide-intrinsic features.
(A) Number of MHC class I and II neoantigens/mHA per tumor model contained within the 
study. (B) Schematic of neoantigen/mHA prediction and ELISpot validation workflow. (C) 
Summary of the major classes of peptide-intrinsic features identified for each antigen, 
including amino acid sequence and characteristics at I) each absolute position, II) each 
relative site, III) the mutation position, and IV) the start, middle, and end of each peptide. 
Red boxes around columns in I) demonstrate each absolute position and in IV) demonstrate 
the start, middle, and end distinctions. Red lettering in III) provides an example for SNV 
mutation site between reference and antigenic sequences.
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Figure 2: Linear regression analysis between peptide-intrinsic features and tumor antigen 
immunogenicity.
(A and C) Volcano plots representing the generalized linear method (GLM) coefficient (x-
axis) and −log10(q-value)(y-axis) for each peptide-intrinsic feature as a predictor for 
immunogenicity in (A) class I and (C) class II neoantigens/mHA. Dashed line represents q-
value=0.05. Spot color represents −log10(q-value) magnitude and size represents magnitude 
of the coefficient. (B,D) Heatmap representing Spearman correlations between each 
significantly correlated feature from (A,C) for (B) class I and (D) class II neoantigens/mHA, 
respectively. Colored cells represent significantly correlated features (q<0.05), with 
magnitude of the correlation coefficient represented by color. (E) ELISpot-derived 
immunogenicity scores for class I neoantigens/mHA classified as predicted high (>100) or 
low (<100) immunogenic by multivariable GLM regression. Data represent median (middle 
line), with boxes encompassing the 25th to 75th percentile, whiskers encompassing 1.5× the 
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interquartile range from the box, and independent values shown by dots. Statistics performed 
with Mann-Whitney U-test, with significance defined as p<0.05.
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Figure 3: Performance and validation of the gradient boosting model (GBM) approach for 
predicting neoantigen/mHA immunogenicity.
(A) Schema of the cross-validation approach used for GBM model building. (B) 
Performance of the final GBM model in validation set, showing actual (x-axis) versus 
predicted (y-axis) immunogenicity scores. Size of each point represents number of antigens 
at each coordinate. Red line represents the line of best fit, with p-value of fit shown above 
the graph. (C,E) Schema for in vivo validation experiments, with tumor vaccine studies 
performed in (C) BBN963 basal-like bladder cancer and (E) the P815 mastocytoma 
syngeneic transplant model. (D,F) Kaplan-Meier survival curves for animals bearing (D) 
BBN963 basal-like bladder cancer and (F) P815 mastocytoma syngeneic transplants. 
Animals treated with predicted high (red) or low (blue) immunogenicity antigens, no-peptide 
control (black), or bone marrow only control (grey). Data in (D) represents two independent 
experiments. Data in (F) represents one independent experiment. Statistics performed with 
log-ranked testing (**p<0.01; ***p<0.001).
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Figure 4: Correlative analysis of predicted neoantigen immunogenicity in TCGA human 
datasets.
(A) Volcano plot representing generalized linear method generalized linear method (GLM) 
coefficient (x-axis) and −log10(q-value)(y-axis) between numbers of highly immunogenic 
neoantigens (HINs) and immune gene signatures (IGSs) in TCGA pan-cancer datasets. (B) 
Heatmap representing GLM regression between numbers of HINs and IGS for each TCGA 
cancer subset. Color represents direction of coefficient (red: positive; blue: negative), and 
shade represents −log10(q-value) magnitude. (C) Number of HINs (x-axis) versus 
microsatellite instability (MSI) score (y-axis) for a TCGA colorectal carcinoma (COAD) 
dataset. (D) Volcano plot representing GLM coefficient (x-axis) and −log10(q-value)(y-axis) 
between average expression of IGS in (B) with significantly negative association with HIN 
burden and oncogene/tumor suppressor copy numbers in a TCGA lung adenocarcinoma 
(LUAD) dataset. (A,D) Dashed line represents q-value=0.05.
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Figure 5: Analysis of out-of-frame epitope B2-specific T cells.
(A) Percent B2 tetramer–positive (left) versus irrelevant SIINFEKL-tetramer control (right) 
BBN963 tumor-infiltrating CD8+ T cells. Statistics performed with Mann-Whitney u-test 
(*p<0.05). (B) 4-hour flow cytometric cytotoxicity assay, comparing percent specific killing 
in 1:1 cocultures of B2 tetramer–specific T cells or OTI irrelevant T-cell controls versus 
BBN963 target or irrelevant splenocyte target control. Percent killing represents spontaneous 
target death background subtracted values. Statistics not performed for (B) due to n=2 
sample size across all groups. (C) 4-hour chromium-51 release assay, comparing percent 
specific killing in cocultures of B2 tetramer–specific T cells or OTI irrelevant T-cell controls 
versus BBN963 targets at 10:1 and 5:1 effector-to-target ratios. (A-C) Error bars represent 
mean±standard deviation. Data from each graph represents one independent experiment, 
respectively. Statistics performed with Welch’s t-test (**p<0.01; *p<0.05).
Smith et al. Page 25
Cancer Immunol Res. Author manuscript; available in PMC 2020 April 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
